PeptiMimesis
Illkirch
About PeptiMimesis
PeptiMimesis is a strategic partner in the design, the discovery and the early development of transmembrane therapeutic peptides. Our innovative approach enables the identification of peptidomimetic candidates interfering with the hetero- and/or the homodimerization of target receptors. PeptiMimesis will develop its pipeline against key targets in the fields of oncology, immuno-oncology and immune disease and is open to initiate collaboration with pharma partners on receptors of interest.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $2.2M
- Funding stage: Seed
- Last round: Seed (Mar 2017)
- Website: peptimimesis.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/peptimimesis-104013 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.